Neurosense Therapeutics is trading 6.96% up at $0.41, supported primarily by a broader biotech-sector rally, with XBI up 2.06% during the regular session.
- No confirmed company-specific catalyst was identified for August 26, 2026.
- Investors are monitoring the August 26 special shareholder meeting on authorization for a potential 1-for-4 to 1-for-40 reverse split; available reporting does not establish it as the direct cause.